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Original article
Background: The early-onset sepsis (EOS) calculator was 
developed and validated in a setting with routine-based group B 
Streptococcus (GBS) screening.
Purpose: The study aimed to evaluate the extent of influence 
exerted by risk-based GBS screening on management recom-
mendations by the EOS calculator.
Methods: All newborns with a gestational age greater than 35 
weeks were screened for EOS risk factors in a Dutch regional 
teaching hospital using a risk-based GBS screening strategy. We 
calculated the EOS risk at birth and stratified the infants into the 
following 3 risk levels with corresponding management recom-
mendations: low, <0.65; intermediate, 0.65–1.54; and high, 
>1.54 per 1000 live newborns. Thereafter, we recalculated the 
EOS risk and recommendation for the newborn infants without 
available maternal GBS screening results at birth.
Results: In one year, 1,877 eligible births occurred; of them, 
206 infants were included. Maternal GBS status was available 
for 28 of 206 infants (14%) at birth, while a definitive GBS 
status was later available for 162 of 206 infants (79%). Median 
EOS risk was slightly lower after definitive GBS status was 
determined (0.41 vs. 0.46 per 1,000 live births, P=0.004). 
In 199 of 206 newborn infants (97%), the EOS calculator re-
commendation remained unchanged after the GBS results 
unavailable at birth were updated to definitive GBS status. 
Use of GBS status at birth versus definitive GBS status did not 
result in the withholding of antibiotic treatment of the newborn 
infants included in this study.
Conclusion: Risk-based GBS screening is compatible with 
EOS calculator recommendations. Larger studies are needed 
to develop the best strategy for combining GBS screening and 
EOS calculator recommendations.
Key words: Early-onset sepsis, Group B Streptococcus, Mater-
nal screening, Neonatal, Sepsis calculator
Key message
Question: To what extent does risk-based Group B Streptoco­
ccus (GBS) screening influence management recommenda-
tions by the early-onset sepsis (EOS) calculator?
Finding: In 97% of the newborn infants, the EOS calculator 
recommendation remained unchanged after the GBS status at 
birth was updated to the definitive GBS status.
Meaning: Risk-based GBS screening results are compatible with 
EOS calculator recommendations.
Introduction
Maternal colonization with Group B Streptococcus (GBS) 
is a risk factor for neonatal sepsis, as vertical transmission in 
utero or during labor can result in a life-threatening early-onset 
sepsis (EOS) in the newborn infant.1) In the United States, 
GBS colonization is therefore extensively determined among 
pregnant women, with screening rates at 85% or higher.2) This 
universal routine-based screening strategy contrasts with the 
heterogeneous practice worldwide. For example, in Europe 
various guidelines advocate risk-based GBS screening depending 
on obstetric history, whereas in Korea guidelines for the screening 
of pregnant women for GBS still need to be established.3-7) A 
recent study found a GBS colonization rate of 11.6% among 
pregnant Korean women and recommended GBS screening and 
the administration of intrapartum antibiotic prophylaxis (IAP) 
in pregnant Korean women.4) The status of maternal vaginal or 
rectal GBS colonization needs to be available in labor to allow 
timely administration of IAP to prevent EOS.3) Partly attributed 
to IAP, a decline in the incidence of EOS to less than 0.5 in 1,000 
live births has been observed among term infants.8) However, the 
reported number of infants receiving empiric antibiotic therapy 
for suspected EOS is much higher.9)
To improve the accuracy of empirical antibiotic administration 
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3. EOS calculator
The EOS calculator is a multivariate risk assessment based 
on 5 maternal objective risk factors and the newborn infant’s 
clinical condition to estimate each infant’s risk of EOS. The 5 
maternal risk factors are gestational age, duration of rupture of 
membranes, highest intrapartum maternal temperature, use 
of intrapartum antibiotics (considered adequate prophylaxis 
if administered more than 4 hours before birth), and maternal 
GBS status. The EOS calculator allows ‘positive,’ ‘negative,’ and 
‘unknown’ as input for maternal GBS status in the algorithm. 
We used ‘unknown’ in cases where GBS test results were un-
available at time of EOS calculator application. To assess the 
clinical condition attending physicians were trained to define the 
newborn infant’s clinical appearance status (‘well-appearing,’ 
‘equivocal exam,’ or ‘clinical illness’) according to definitions 
published along with the EOS calculator.17,18) For each included 
infant we calculated the EOS risk at birth, using a prior EOS 
probability of 0.6 per 1,000 livebirths, and we stratified newborn 
infants into 3 levels of risk (low: <0.65; intermediate: 0.65–1.54; 
high:> 1.54 per 1,000 live newborns) with a corresponding 
recommendation on management. This recommendation con-
sisted of standard care, monitoring of vital signs every 3 hours, or 
the start of empirical antibiotic therapy, respectively.
4. Data analysis
For this study, we retrospectively collected the results of all 
maternal blood, urine, genital and anorectal cultures performed 
at any time during pregnancy or delivery. We calculated EOS 
risk and recommendation for each included newborn infant 
after birth (Fig. 1). We recalculated the EOS risk and recom-
mendation for those newborn infants in whose mothers the 
in newborn infants at risk for EOS, the neonatal EOS calculator 
was designed and validated in the United States. It has proven to 
be effective in limiting antibiotic treatment in suspected EOS in 
term and near-term infants without apparent adverse effects.10-15) 
The sepsis calculator uses maternal GBS status at birth as 1 of 
5 maternal risk factors. The EOS calculator allows ‘positive,’ 
‘negative,’ and ‘unknown’ as input for maternal GBS status in 
the algorithm. In contrast to a routine-based GBS screening, 
risk-based GBS screening carries the possibility that maternal 
GBS colonization information is unavailable at time of birth. 
Often, the GBS culture results become later available after birth. 
As the EOS calculator is being evaluated for implementation in 
European and Asian practice, it is important to know whether 
implementation is compatible with risk-based GBS screening.
The aim of this study was to evaluate to what extent a risk-
based GBS screening influences management recommendations 
by the EOS calculator. If our results indicate that antibiotic re-
commendations are not influenced by this strategy than the 
sepsis calculator may also be implemented in countries with a 
risk-based GBS screening policy.
Methods
1. Study population
We used data from our EOS calculator implementation study 
in a Dutch regional teaching hospital (Tergooi Hospital).15) 
Briefly, we prospectively screened during a single year (April 
2016 through March 2017) all newborn infants born at a 
gesta tional age of 35 weeks or more, for risk factors or clinical 
signs of EOS. EOS risk factors included prematurity, maternal 
fever (≥38°C), positive maternal GBS status, rupture of mem-
branes for more than 24 hours before birth, and presumed 
chorioamnionitis with or without IAP. Newborn infants were 
included if either one or more maternal risk factors for EOS 
and/or clinical signs of EOS were present. All data regarding 
maternal risk factors and the results of the physical examination 
of the newborn infant were collected through a case report form 
by the attending physician. Exclusion criteria were birth outside 
Tergooi Hospital. This study was approved by the Scientific 
Review Committee of Tergooi Hospitals (study number 15.58; 
letter reference kV/15.69).
2. GBS screening protocol
According to Dutch national guidelines, maternal GBS screen-
ing was performed depending on obstetric history (risk-based 
GBS screening). Screening was performed in case of prematurity, 
defined as a gestational age less than 37 weeks, rupture of mem-
branes for more than 18 hours, maternal fever higher than 38°C 
during delivery, or a history of a previous child with GBS-related 
disease.16) The Dutch guidelines advise IAP in case of a GBS-
positive urine culture to prevent GBS-disease.5)
1,877 Born in 
Torgooi Hospital
1,669 No EOS risk factors 
or symptoms
2 Missing data
206 EOS risk factor or symptom;
Pre- or intra-partum GBS screening if indicated according to local 
protocol








206 Original sepsis 
calculator recommendation
206 Adjusted sepsis calculator 
recommendation
Fig. 1. Study design and inclusion criteria. Flowchart of study design and 
inclusion criteria. Numbers denote the number of newborns. EOS, early-
onset sepsis; GBS, group B Streptococcus.
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GBS culturing results were unavailable at time of birth. This was 
defined as definitive GBS status. We compared EOS risk and 
recommendation at birth and after completing the definitive 
GBS status. We used Wilcoxon signed-rank test with an alpha-
level set at P<0.05 to determine statistical significance. Data 




During the study period, 1,877 eligible births occurred. Among 
these, 208 newborn infants fulfilled the inclusion criteria and 206 
had sufficient data to be included in the analysis. Inclusion was 
due to the presence of one or more maternal risk factors in 183 
of 206 (89%), the presence of clinical symptoms in the newborn 
infant in 13 of 206 (6%), or a combination of both in 11 of 206 
(5%). Newborn infants were predominantly male (57%), median 
gestational age was 39 weeks (interquartile range, 37–40 weeks).
Maternal GBS status was available for 28 of 206 (14%) of 
included newborn infants at birth, mainly from cultures per-
formed during pregnancy. A definitive GBS status was deter-
mined for 162 of 206 newborn infants (79%) (Table 1). Twelve 
of these included a positive urine culture, of which 6 (50%) were 
adequately treated with intrapartum antibiotics.
2. GBS status and EOS calculator results
We compared EOS risk and recommendation as generated 
by the EOS calculator at birth and after completing a definitive 
GBS status (Table 1). Median EOS risk was slightly lower using 
the definitive GBS status (0.41 vs. 0.46 per 1,000 live births, 
P=0.004). EOS calculator recommendation changed in 7 of 
206 (3%) of newborn infants. Three were assigned a recom-
mendation for clinical observation using vital signs, instead of 
‘no additional care’; this was the opposite for another 3 infants. 
Use of the definitive GBS status did not lead to additional re-
commendations for empirical antibiotic therapy; in 1 case the 
recommendation changed from antibiotic treatment to clinical 
observation (Fig. 2).
Discussion
As use of the EOS calculator spreads to areas without uni-
versal screening for GBS, it is important to consider how use 
of other screening strategies may impact recommendations 
by the EOS calculator. In particular, it is important to address 
whether the lack of universal GBS screening may lead to fewer 
recommendations of antibiotic therapy. We found that in 97% 
of newborn infants at risk for EOS in a single Dutch center, the 
EOS calculator recommendation remained unchanged after we 
recalculated the EOS risk using the definitive GBS results, which 
were not yet available at birth. Median EOS risk was slightly 
lower after recalculation using the definitive GBS screening 
results. Most importantly, additional knowledge on the GBS 
status did not increase the total number of recommendations 
for antibiotic treatment in newborn infants with a GBS-positive 
mother. In other words, the risk-based screening method did not 
withhold antibiotic treatment in infants at risk for EOS. These 
observations together indicate that use of a risk-based screening 
method only marginally influences EOS calculator management 
recommendations.
These findings correspond with the modest contribution of 
the GBS status as a risk factor to the total predictive value in the 
multivariate EOS calculator model.18) They are further explained 
by the finding that definitive GBS results were mostly negative, 
Table 1. GBS test results and EOS calculator results of newborns 
before versus after definitive maternal GBS status availability










Positive   19   33 N/A
Negative     9 129
Unknown 178   44
EOS risk, median (IQR) 0.46 (0.19–0.89) 0.41 (0.17–0.85) 0.004
Recommendation
NAC 141 142 0.655
Vitals every 3 hours   38   37
Start empiric antibiotics   27   27
GBS, group B Streptococcus; EOS, early-onset sepsis; IQR, interquartile 
range; NAC, no additional care; N/A, not applicable.
Boldface indicates a statistically significant difference with P<0.05.
Fig. 2. EOS calculator recommendation changes resulting from 
definitive GBS status. Changes in EOS calculator recommendation after 
adjusting for definitive GBS carrier information unavailable at birth using 
the risk-based GBS screening. Numbers denote the number of newborns 
affected by the related category change. EOS, early-onset sepsis; GBS, 
group B Streptococcus.
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thus decreasing EOS risk. In our study population, GBS status 
was available at birth in only few cases, whereas a definitive GBS 
status was determined in the vast majority of cases. This indicates 
that GBS screening shortly prior to birth is common with a 
risk-based screening strategy, limiting the opportunity to timely 
administer IAP. A definitive GBS status was not determined in the 
remaining fifth of our study population, most likely because of 
absence of indications for testing in obstetric history. Importantly, 
a substantial part of GBS-related EOS disease occurs despite 
negative GBS status,19) reflecting that other factors and clinical 
signs should be taken into account at all times.
Maternal GBS status can mediate the calculated EOS risk and 
management guided by the EOS calculator indirectly through 
IAP, which is widely used to decrease GBS-related EOS.20) 
Notable differences across guidelines and in practice exist,5,21) 
but Dutch guidelines recommend IAP in case of a positive urine 
culture.5) We found that in our population only 6% of tested 
mothers qualified for IAP as a result of a GBS-positive urine 
culture. Only half of these mothers received adequate intrapar-
tum antibiotics, possibly due to late availability of results of ma-
ternal GBS screening.
As use of the EOS calculator spreads to areas with various 
approaches regarding prevention of GBS neonatal sepsis, this 
development should be accompanied with thoughtful evalu-
ation of GBS screening strategies. Our findings indicate that 
use of risk-based GBS screening only marginally impacts EOS 
calculator antibiotic management recommendation in the new-
born infant. However, GBS screening strategies may be most 
– if not only – helpful when results are provided timely enough 
for administration of IAP and for use in the EOS calculator. The 
new generation of rapid intrapartum tests based on polymerase-
chain-reactions is a promising opportunity in this matter.22,23) 
Rapid availability of results will be more suitable for guiding 
decisions on timely IAP and for direct use in the EOS calculator 
at birth.
Among the strengths of our study is its thorough data collec-
tion on maternal GBS status. Also, to our knowledge, this is the 
first study to evaluate the important difference in GBS screen-
ing strategies in the context of the increasingly adopted EOS 
calculator. Limitations include the single-center study design, 
which means that results may be different in settings with dif-
ferent risk-based screening strategies. It was conducted in a 
high-risk population subset with limited sample size, selected 
on presence of maternal EOS risk factors or neonatal clinical 
EOS symptoms. The results therefore cannot be generalized to 
the general newborn infant population without precautions. 
However, the remaining population of the newborn infants 
in our hospital had no known EOS risk factors or clinical EOS 
symptoms. It is therefore at low risk for EOS, and thus unlikely 
to receive an EOS calculator recommendation for empiric anti-
biotic therapy, irrespective of maternal GBS status. Hence, we 
are confident that our design included the vast majority of rele-
vant births where GBS status could have a significant role in 
decisions regarding empiric antibiotic therapy, making the results 
indicative for the larger population. Finally, although these 
results are supportive of the applicability of the EOS calculator 
in settings with a risk-based screening strategy, this study does not 
validate the EOS calculator itself for such settings.
In conclusion, our results indicate that use of risk-based GBS 
screening is compatible with use of the EOS calculator. Larger 
studies are needed to address the best way of combining GBS 
screening with use of the EOS calculator.
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